March 2026

RHEUMATOLOGY

STUDY DEFINES RANGE FOR EFFECTIVE HYDROXYCHLOROQUINE BLOOD LEVELS IN LUPUS

Hydroxychloroquine (HCQ) is a foundational therapy for systemic lupus erythematosus (SLE), yet concerns about long‑term toxicity, particularly retinal and cardiac toxicity, often lead to dose reductions, nonadherence or early discontinuation, according to a study published in Arthritis & Rheumatology featuring Rosalind Ramsey-Goldman, MD, DrPH, a co‑investigator on the study.
​
Weight‑based dosing alone does not account for variability in drug clearance, especially in patients with chronic kidney disease (CKD). This large, multinational analysis defines an evidence‑based therapeutic reference range for HCQ blood levels, supporting a shift toward precision drug monitoring in lupus.

Study Overview
  • Population: 2,010 patients with SLE from U.S., international, French, and SLICC cohorts
  • Primary analysis: 1,842 patients (excluding very low HCQ levels <200 ng/mL associated with severe nonadherence)
  • Approach: Cross‑sectional analyses using adjusted spline and multivariable logistic regression

Key Findings
  • Therapeutic HCQ blood‑level range identified: 750 to <1,150 ng/mL.
  • HCQ blood levels ≥1,150 ng/mL were associated with:
  1. 2.1‑fold higher odds of HCQ‑related toxicity
  2. No further reduction in lupus disease activity, demonstrating a clear ceiling (saturation) effect
  • HCQ blood levels <750 ng/mL were associated with significantly higher odds of active lupus.
  • Each additional 1,000 grams of cumulative HCQ dose was associated with a 1.7‑fold increase in toxicity risk, after adjustment for weight‑based dosing and other covariates.

Kidney Disease Is a Key Risk Factor
  • Patients with CKD stage ≥3 (eGFR <60 mL/min/1.73 m²) had 2.3‑fold higher odds of having supratherapeutic HCQ levels (≥1,150 ng/mL).
  • Even at ≤5 mg/kg/day, predicted HCQ blood levels in CKD stage ≥3 were near or above the supratherapeutic threshold.
  • Longitudinal modeling in a subset of patients with CKD stage ≥3 suggested that a 20‑unit decline in eGFR could raise HCQ blood levels by approximately 96 to 122 ng/mL, depending on dose category.

Weight‑Based Dosing Alone Falls Short
  • 18% of patients had supratherapeutic HCQ levels despite receiving ≤5 mg/kg/day.
  • 37% of patients on >5 mg/kg/day had supratherapeutic levels.

These findings demonstrate that weight‑based dosing does not reliably prevent supratherapeutic or potentially toxic HCQ levels, particularly in patients with impaired renal function.

Clinical Implications
  • Monitor HCQ blood‑level routinely to balance efficacy and safety.
  • Identify patients at higher risk for toxicity, especially those with CKD stage ≥3.
  • Move beyond one‑size‑fits‑all dosing toward individualized, data‑driven HCQ management.

​This study defines a therapeutic reference range for hydroxychloroquine whole‑blood levels (750–1,150 ng/mL) using data from diverse multinational lupus cohorts. Levels above this range increase toxicity risk without improving disease control, while lower levels are associated with active disease. The findings strongly support precision drug monitoring, particularly for patients with reduced kidney function and lay the groundwork for future longitudinal studies to guide personalized HCQ dosing in SLE.
Rosalind Ramsey-Goldman, MD, DrPH, John P. Gallagher Research Professor of Rheumatology at Northwestern Medicine  

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like